Disclosed herein is a method of making polymerizable bio-based monomers containing one phenolic hydroxyl group which has been derivatized to provide at least one polymerizable functional group which is an ethylenically unsaturated functional group (such as a [meth]acrylate group), where the precursors of the polymerizable bio-based monomers are derived from raw lignin-containing biomass. Also disclosed herein are bio-based copolymers prepared from such bio-based monomers and a co-monomer, and methods of making and using such bio-based copolymers. In particular, the bio-based copolymers can be used as pressure sensitive adhesives, binders, and polymer electrolytes.

Disclosed herein is a method of making polymerizable bio-based monomers containing one phenolic hydroxyl group which has been derivatized to provide at least one polymerizable functional group which is an ethylenically unsaturated functional group (such as a [meth]acrylate group), where the precursors of the polymerizable bio-based monomers are derived from raw lignin-containing biomass. Also disclosed herein are bio-based copolymers prepared from such bio-based monomers and a co-monomer, and methods of making and using such bio-based copolymers. In particular, the bio-based copolymers can be used as pressure sensitive adhesives, binders, and polymer electrolytes.

A Ziegler-Natta catalyst composition is disclosed. The catalyst composition includes an internal electron donor with improved polymerization kinetics, a long lifetime, improved stereoselectivity and/or improved hydrogen response.

A Ziegler-Natta catalyst composition is disclosed. The catalyst composition includes an internal electron donor with improved polymerization kinetics, a long lifetime, improved stereoselectivity and/or improved hydrogen response.

A nonionic Gemini surfactant, (octylphenol polyoxyethylene ether disubstituted) dicarboxylic acid diphenyl ether has a structural formula of: ##STR00001##
and is prepared by a two-step reaction: S1, diphenyl ether 4,4′-dicarboxylic acid is subjected to an acyl chlorination reaction to obtain diphenyl ether 4,4′-dicarbonyl dichloride; S2, diphenyl ether 4,4′-dicarbonyl dichloride is subjected to an esterification reaction with octylphenol polyoxyethylene ether (OP-10) to obtain the target product (octylphenol polyoxyethylene ether disubstituted) dicarboxylic acid diphenyl ether. The surfactant is expected to be applied in tertiary oil recovery as an alkali/surfactant, in polymer/surfactant binary composite flooding, in alkali/surfactant/polymer ternary composite flooding, as a microemulsion emulsifier and the like, and it can also be compounded with a common surfactant to reduce the use cost, and thus create conditions for its large-scale application.

A nonionic Gemini surfactant, (octylphenol polyoxyethylene ether disubstituted) dicarboxylic acid diphenyl ether has a structural formula of: ##STR00001##
and is prepared by a two-step reaction: S1, diphenyl ether 4,4′-dicarboxylic acid is subjected to an acyl chlorination reaction to obtain diphenyl ether 4,4′-dicarbonyl dichloride; S2, diphenyl ether 4,4′-dicarbonyl dichloride is subjected to an esterification reaction with octylphenol polyoxyethylene ether (OP-10) to obtain the target product (octylphenol polyoxyethylene ether disubstituted) dicarboxylic acid diphenyl ether. The surfactant is expected to be applied in tertiary oil recovery as an alkali/surfactant, in polymer/surfactant binary composite flooding, in alkali/surfactant/polymer ternary composite flooding, as a microemulsion emulsifier and the like, and it can also be compounded with a common surfactant to reduce the use cost, and thus create conditions for its large-scale application.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention reports the obtaining of carbonyl compounds and derivatives, through syntheses with high yield and purity, providing anti-humoral active principles with selective antiproliferative properties and anti-metastatic activity.

The present invention refers to the development of new polyfunctional push-pull butadienes and their O and C-prenylated, benzoylated and iodide derivatives, with high electronic conjugation in the lateral chain. These compounds exhibit high anti-tumor selectivity, causing cell death by apoptosis, also show anti-metastatic and non-mutagenic properties in the experimental studies performed.